ARCA Biopharma and Oruka Therapeutics agree to merge in an all-stock deal, forming Oruka Therapeutics (ORKA) with a $275M private investment.

ARCA Biopharma and Oruka Therapeutics have agreed to merge in an all-stock transaction. Oruka Therapeutics, a privately-held biotech firm, is focused on developing novel biologics for chronic skin diseases, with a pipeline including ORKA-001 and ORKA-002. Upon completion, the combined company, named Oruka Therapeutics, will trade on Nasdaq under the ticker "ORKA". The deal is supported by a $275M private investment, anticipated to fund operations through 2027.

April 03, 2024
5 Articles

Further Reading